Core Viewpoint - The National Healthcare Security Administration (NHSA) has initiated a standardization of pricing for radiological examination services, aiming to reduce unreasonable regional disparities in pricing across provinces [1][5]. Group 1: Pricing Adjustments - Since 2025, multiple provinces have adjusted the pricing standards for common imaging examinations such as CT, MRI, and X-rays, with significant price reductions observed in high-cost procedures like PET/CT [1][2]. - In Shaanxi Province, the price for PET/CT has been reduced from over 4200 yuan to 2450 yuan, representing a nearly 40% decrease [2][6]. - The new pricing system categorizes examination items into seven major categories, including X-ray, CT, MRI, and PET/CT, with a total of 233 old items being consolidated into 26 new items [2][4]. Group 2: Digital Transformation - The new regulations eliminate the bundling of physical film with examination prices, allowing patients to access cloud imaging conveniently through mobile devices [3][6]. - If public medical institutions do not provide compliant digital imaging and cloud storage services, the examination price will be reduced by 5 yuan [3]. Group 3: Market Dynamics - The price adjustments are closely linked to centralized procurement of medical equipment and accelerated domestic substitution, which have significantly lowered procurement costs for hospitals [6][7]. - The price of large imaging equipment like CT scanners has decreased by 40% over the past decade, with domestic equipment accounting for 50% of the market share in 2023 [6][7]. Group 4: Financial Implications - The annual costs for film and repeated examinations in resource-rich provinces could reach up to 50 billion yuan, potentially freeing up over 800 billion yuan annually if implemented nationwide [7]. - The new pricing rules focus on examination effectiveness rather than equipment parameters, promoting a more rational pricing structure based on clinical value [7]. Group 5: Future Outlook - The adjustments aim to balance patient costs and service efficiency, encouraging hospitals to improve operational efficiency in equipment use and service processes [7]. - Companies in the medical device sector will need to enhance service value and align with policies to sustain long-term growth amid pricing pressures [7].

以下文章来源于健闻咨询 ，作者健闻咨询 健闻咨询 . 医疗行业跨界洞察 本文来自微信公众号： 健闻咨询 ，作者：乔燕薇、李琳，原文标题：《医疗服务价格改革再推进： 放射科、检验科降幅明显，医院迫切想知道怎么"回血"？》，题图来自：AI生成 刚刚过去的8月，国家医保局再次接连印发三项《医疗服务价格项目立项指南 （试行） 》，涉及物 理治疗类、消化系统，以及疝、甲乳类。至此， 本轮医疗服务价格改革已印发33批次， 各地的落地 进展也步履不停。 作为改革主阵地的医院，正在感受改革过程不同程度的冲击。 凡涉及改革和调整的医院，大多向健闻咨询表达了一种共同的感受： 不同学科的调价幅度有明显不 同，这种变化正在重塑医院内不同科室的收入结构。 与上一轮DRG/DIP改革的影响类似的是，在医疗服务价格改革中，不同学科的医疗服务价格有升有 降，各个科室的运营收入多少也会随之变化。 其中，最为瞩目的是以设备物耗占比为主的检查化验类项目的价格调整。在已经开始推进项目落地的 内蒙古、山东、江苏等地区， 放射科与检验科医疗服务项目价格，均出现明显下降。 在医疗服务价格改革进展较快的试点地区，一家医院的医保科工作人员季明明 （化名） 表 ...

Policy Developments - The National Healthcare Security Administration issued the "Guidelines for the Project Establishment of Physical Therapy Medical Service Price (Trial)" which integrates existing price projects into 32 items, with 7 additional charges and 1 expansion item [2] Medical Device Approvals - In July, the National Medical Products Administration approved the registration of 295 medical device products, including 240 domestic Class III medical devices, 21 imported Class III medical devices, 29 imported Class II medical devices, and 5 products from Hong Kong, Macau, and Taiwan [4] Company Announcements - New Industries announced that 18 of its chemiluminescent reagent products received IVDR CE certification, allowing them to enter the EU market, which is expected to enhance the company's competitive edge [5] - Jimin Health reported a net loss of 52.7 million yuan for the first half of 2025, with revenue of 366 million yuan, a year-on-year decrease of 21.3% [9] - Zhongyao Holdings disclosed a net profit of 282 million yuan for the first half of 2025, with revenue of 41.188 billion yuan, reflecting a year-on-year growth of 3.54% [8] - Jinling Pharmaceutical received a drug re-registration approval for hydrolyzed protein injection, which is used for severe amino acid deficiency due to major surgeries and other diseases [6] - Chenguang Biological announced plans to transfer 97.5% of its subsidiary Chenguang Tianrun Pharmaceutical to Sichuan Tongsheng Biological Medicine, with the transfer based on the subsidiary's book equity as of July 31, 2025 [11] - Baiyang Pharmaceutical's controlling shareholder plans to increase capital and change the equity structure, with a new entity set to acquire 80% of the controlling group [12] Industry Events - A groundbreaking cervical spine surgery was successfully performed in Shanghai, utilizing innovative "satellite plate" technology to stabilize a severely injured patient's spine [14] - Guangxi plans to provide free HPV vaccinations to nearly 960,000 eligible girls from 2025 to 2027, emphasizing the importance of preventive healthcare [15] Shareholder Actions - Multiple shareholders of Sanxin Medical plan to reduce their holdings due to personal financial needs, with specific share amounts outlined for each individual [17]

Core Viewpoint - The article discusses the recent developments in China's healthcare reform, particularly focusing on the medical device industry, highlighting the shift towards quality-driven procurement, credit evaluation systems, and the integration of innovative technologies into the healthcare payment system. Group 1: Procurement and Quality Control - The 11th batch of national drug procurement has been officially launched, emphasizing four principles: stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition [2] - New rules require that production lines must not have GMP violations within two years, and all selected companies must undergo comprehensive inspections [3] - The trend of "de-emphasizing low prices" is accelerating in high-value consumables procurement, with new mechanisms like clinical recommendations and quality reviews being introduced [3] Group 2: Credit Evaluation System - A dual-dimensional credit evaluation system has been established to address issues of market manipulation and excessive pricing by some companies [4] - By the end of 2024, 735 companies have been identified as untrustworthy, leading to restrictions on their procurement qualifications [4] - The new market entry logic emphasizes compliance and quality-driven operations, marking a shift from previous practices [4] Group 3: Pricing and Payment Reforms - The National Healthcare Security Administration (NHSA) is actively managing price risks, having completed eight rounds of price checks involving 566 companies and 726 product specifications [5] - The payment model has shifted from a "post-payment" to a "pre-payment" system, with total healthcare expenditure expected to reach 2.98 trillion yuan in 2024, reducing patient out-of-pocket expenses by approximately 5% [9] - The integration of innovative technologies into the payment system is accelerating, particularly for companies involved in AI imaging and interventional consumables [10] Group 4: Immediate Settlement and Direct Payment - The immediate settlement mechanism has been implemented in 91% of the national healthcare areas, reducing the settlement cycle from 30 to 20 working days [11] - The direct payment mechanism for selected companies is being promoted, which could significantly benefit cash-sensitive small and medium-sized medical device companies [11] Group 5: Regulatory Oversight and Compliance - The NHSA is enhancing its regulatory oversight, with a focus on compliance and transparency in the supply chain [12] - The establishment of big data models for monitoring healthcare practices is underway, with a focus on identifying and addressing fraudulent activities [14] - Future regulations will emphasize the tracking of medical devices and the ability to close data loops, which will directly impact market performance [17] Group 6: Innovations in Medical Services - The NHSA is accelerating reforms in medical service pricing, with over 100 projects focusing on cutting-edge technology and urgent clinical needs [18] - This creates a pathway for the integration of innovative medical devices into clinical use, payment, and service pricing [19] Group 7: Strategic Directions for Medical Device Companies - The article outlines five key areas for medical device companies to focus on in light of the ongoing healthcare reforms, emphasizing the need for quality, compliance, and value recognition [20][23]

Core Insights - The article discusses the significant reduction in medical service prices in China, particularly focusing on hemodialysis costs, which have dropped below 300 yuan, benefiting over one million dialysis patients [1][3][5] Group 1: Hemodialysis Price Reform - In 2024, the number of patients requiring dialysis in China is projected to reach 1.027 million, highlighting the critical need for affordable treatment options [1] - The National Healthcare Security Administration (NHSA) has issued guidelines to consolidate hemodialysis pricing, reducing the number of pricing items from 421 to 108, aiming to eliminate duplicate charges [3][8] - Provinces like Guangdong and Hunan have already implemented new pricing structures, with Guangdong setting a maximum price for hemodialysis at 390 yuan per session, while Hunan has established a base price of 330 yuan [5][7] Group 2: Broader Medical Service Price Reforms - The ongoing medical service price reform is not limited to hemodialysis but encompasses various medical services, with the NHSA aiming to standardize pricing across provinces to address historical discrepancies [8][9] - The NHSA has published 28 batches of project guidelines covering various medical fields, leading to significant price reductions in services such as ultrasound and PET/CT scans [9] - The reforms are designed to enhance transparency in medical pricing, preventing healthcare institutions from imposing additional charges under different names [7][9]

Core Viewpoint - The ongoing reform of medical service pricing is significantly impacting hospitals and healthcare providers, with concerns about revenue implications and the complexity of implementation [1][2][11]. Group 1: Medical Service Pricing Reform - The National Healthcare Security Administration (NHSA) has issued a new guideline for urological medical service pricing, consolidating 421 existing pricing items into 108, with additional charges and expansions [1]. - The NHSA has released 29 batches of the "Medical Service Pricing Project Establishment Guidelines (Trial)" to standardize medical service pricing across regions, but the implementation has been slow and cautious [1][4]. - Some regions, like Inner Mongolia, have successfully implemented over 20 batches, while most areas have only seen 5-6 batches adopted [4]. Group 2: Implementation Challenges - Hospitals express concerns about the impact of the new guidelines on their already fragile revenue, particularly as some new projects do not fully map onto existing ones [2][3]. - The implementation process involves two main steps: mapping existing medical projects to the new guidelines and setting prices, which has proven complex and labor-intensive for hospitals [5][6]. - Hospitals are under pressure to adapt quickly, with some staff feeling unprepared due to missed training sessions [7]. Group 3: Revenue Impact Concerns - There is a widespread fear among hospitals that the pricing reforms will lead to reduced revenue, especially in areas like radiological examinations and clinical assessment scales [8][9]. - For instance, the price of CT scans has dropped from over 300 yuan to around 200 yuan, and MRI scans from 600 yuan to 500 yuan, which could significantly affect hospital income [8]. - The clinical assessment scales have seen a drastic reduction in both the number of items and their prices, raising concerns about the sustainability of revenue from these services [9]. Group 4: Confusion Over Costing and Billing - Hospitals face confusion regarding which consumables can be charged separately, as the guidelines include basic consumables in the project pricing [13][14]. - There is a call for a standardized naming system for medical consumables and a clear directory for billable items to alleviate these concerns [14]. - Some existing local projects are not included in the new guidelines, leading to uncertainty about their future status and whether they will be discontinued [15].

Group 1 - The core viewpoint of the article is that there has been a significant adjustment in medical service pricing across various hospitals in China since June, with a focus on redefining service items and their pricing structures [1][2][3] - The new pricing reforms aim to scientifically leverage pricing tools by adjusting both increases and decreases in service fees, thereby redefining the relationship between service items, medical technologies, and activities [3] - Specific adjustments include the reduction and standardization of comprehensive diagnosis fees, with Guangdong Province consolidating 100 items into 36, allowing hospitals to set prices for certain services [4][5] Group 2 - The maximum limit for outpatient diagnosis fees is set at 25 yuan, with different charges for specialists, while emergency diagnosis fees and ambulance transfer fees are capped at 45 yuan and 75 yuan respectively [6][7] - For inpatient services, the proposed maximum limit for diagnosis fees is 60 yuan, and bed fees range from 56 yuan to 90 yuan depending on the type of room [8][9] - A new "palliative care" service has been introduced with a maximum price of 260 yuan per day to meet diverse patient needs [10] Group 3 - The article highlights that several regions, including Inner Mongolia, have also implemented new pricing standards for comprehensive diagnosis services, with Alxa League reducing certain fees significantly [11][12] - In addition to comprehensive services, there are notable price limits set for traditional Chinese medicine services, with Guangdong consolidating various treatment categories into fewer standardized items [14][15] - The adjustments in traditional Chinese medicine pricing reflect a broader effort to align with national guidelines and improve clarity in service pricing [17][18] Group 4 - The article reports a significant reduction in radiological imaging fees, with various provinces implementing new pricing policies for X-ray and MRI services [25][26] - For example, the maximum fee for X-ray imaging is set at 50 yuan in Guangdong, while MRI scans are priced at 505 yuan, with specific rules for multiple body part examinations [30][31] - The ongoing adjustments are part of a larger initiative by the National Healthcare Security Administration to standardize medical service pricing across the country, addressing discrepancies in service pricing [33][34]

Core Viewpoint - The article discusses a long-term reform in China's medical service pricing system, which aims to unify the vast discrepancies in medical service pricing across different regions, ultimately leading to a standardized national pricing system [1][4][14]. Group 1: Reform Background and Objectives - The reform has been ongoing for 25 years, with multiple changes in management and reform plans [1]. - The goal is to consolidate the 5,000 to 23,000 medical service pricing items across various regions into a consistent national pricing system [1][6]. - The National Healthcare Security Administration (NHSA) has initiated a new round of medical service pricing reform since 2021, with significant acceleration noted in 2024 [1][2]. Group 2: Implementation Challenges - Hospitals are experiencing considerable pressure due to the accelerated pace of the reform, with the complexity of the new guidelines expected to surpass previous reforms like DRG/DIP [3][13]. - The existing chaos in medical service pricing, with over 30,000 items lacking standardization, has led to significant management challenges and confusion in pricing relationships [4][6]. - The NHSA has issued 28 batches of "Project Establishment Guidelines," which include around 1,200 main projects and over 500 additional items, aiming to standardize the pricing structure [8][12]. Group 3: Future Directions and Considerations - The NHSA plans to release all "Project Establishment Guidelines" by 2025, with ongoing efforts to address the complexities of integrating new and existing projects [2][12]. - The new guidelines emphasize the separation of technical costs and consumables, which raises questions about how to charge for new technologies and materials [10][17]. - There are concerns regarding the balance between reflecting clinical labor value, ensuring the sustainability of the healthcare fund, and considering patient affordability [16].

Group 1: Technology Evaluation Mechanism - The meeting emphasized the need to improve the technology achievement evaluation mechanism, focusing on what to evaluate, who evaluates, how to evaluate, and how to utilize the evaluations [4] - A multi-dimensional evaluation system involving government, social organizations, enterprises, and investment institutions is to be established, highlighting the role of enterprises in innovation [4][3] - The evaluation should be based on quality, performance, and contribution, with specific standards for different types of research outcomes [4][3] Group 2: Education Reform - The meeting identified the heavy burden on students in compulsory education as a significant issue, particularly the unregulated growth of extracurricular training institutions [5] - It was stressed that improving school teaching quality is essential to reduce student burdens, alongside a comprehensive reform of educational practices [5] - Strict management and regulation of extracurricular training institutions are to be enforced, with clear standards for fees and operations [5] Group 3: Medical Service Price Reform - The meeting highlighted that medical service pricing is a critical concern for the public, with recent reforms aimed at reducing drug and consumable costs [6][7] - A structured management system for medical service pricing is to be established, balancing the needs of healthcare development with affordability for the public [7] - The importance of a dynamic pricing adjustment mechanism and comprehensive pilot programs for public hospitals was emphasized [7] Group 4: Ecological Protection Compensation - The meeting noted the establishment of ecological compensation mechanisms across various sectors, but highlighted issues such as limited coverage and weak enforcement [8] - A focus on green low-carbon development and comprehensive ecological protection is to be prioritized, integrating legal, administrative, and market approaches [8] - The need for a systematic approach to protect historical and cultural heritage in urban construction was also discussed [8]

Core Viewpoint - The recent implementation of standardized medical service pricing guidelines by the National Healthcare Security Administration aims to unify and regulate medical service pricing across provinces, addressing inconsistencies and confusion in medical billing for patients [1][2]. Group 1: Current Issues in Medical Pricing - Long-standing issues in medical service pricing include significant regional disparities, with some provinces having as few as 4,000 pricing items while others exceed 20,000, leading to confusion and increased billing burdens for medical institutions [2]. - The lack of uniformity in pricing has resulted in unreasonable charges and necessitates a reform to establish standardized pricing, ensuring fair costs for patients [2]. Group 2: Reform Initiatives - The reform initiated in August 2021 aims to create a dynamic pricing mechanism that stabilizes patient costs, ensures the sustainability of public medical institutions, and maintains the affordability of healthcare funds [2]. - The recent acceleration in the issuance of pricing guidelines reflects a systematic overhaul of existing pricing items, clarifying project names, service outputs, and pricing structures [2]. Group 3: Enhancements in Medical Services - New pricing projects have been introduced to enhance accessibility and inclusivity in healthcare, such as "air medical transport" and "home service fees," addressing the needs of an aging population [3]. - The guidelines emphasize the value of clinical personnel's technical labor, particularly for high-difficulty procedures, which is expected to improve service quality and motivate healthcare professionals [3]. Group 4: Implementation and Impact - Successful implementation of the guidelines relies on local healthcare departments and medical institutions actively cooperating to ensure compliance and transparency in pricing [4]. - Following the introduction of the pricing guidelines for radiological services, significant price reductions have been observed, such as the decrease in PET/CT scan costs in Anhui Province, which dropped from 5,000 yuan to 2,500 yuan for single-site scans [4].